Valeria Santini, MD, University of Florence, Florence, Italy, discusses the use of lenalidomide in the treatment of myelodysplastic syndromes (MDS) and the impact of different genetic aberrations on the efficacy of this drug. Dr Santini goes on to outline the use of immunosuppressive treatment in MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).